Company: ANIX
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012701
Chunk: 10

Company: Anixa Biosciences Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 8
Chunk 10
---
 the 2010 Share Plan, the plan terminated with respect to the ability to grant future
awards on July 14, 2020. Information regarding the 2010 Share Plan for the six months ended April 30, 2025 is as follows:

 SCHEDULE OF OPTION ACTIVITY

    Shares  
    Weighted  Average Exercise  Price Per Share  
    Aggregate  Intrinsic Value  (in thousands) 
  
    Options outstanding at October 31, 2024 
     986,968  
    $2.77  

    Options outstanding and exercisable at April 30, 2025 
     986,968  
    $2.77  
    $531 

The following table summarizes
information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2025:

 SCHEDULE
OF OPTIONS OUTSTANDING AND EXERCISABLE

    Range of  Exercise Prices  
    Number  Outstanding and  Exercisable  
    Weighted Average  Remaining  Contractual Life  (in years)  
    Weighted  Average  Exercise Price 
  
    $
    0.67 - $2.27  
     316,000  
     2.3  
    $1.11 
  
    $
    2.58 - $3.13  
     251,968  
     0.8  
    $2.93 
  
    $
    3.46 - $5.30  
     419,000  
     3.0  
    $3.93 

2018 Share Plan

The 2018 Share Plan provides for
the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock
units to employees, directors and consultants. As of April 30, 2025, the 2018 Share Plan had 645,000 shares available for future grants.
Information regarding the 2018 Share Plan for the six months ended April 30, 2025 is as follows:

 SCHEDULE
OF OPTION ACTIVITY

    Shares  
    Weighted  Average Exercise  Price Per Share  
    Aggregate Intrinsic Value (in thousands) 
  
    Options outstanding at October 31, 2024 
     11,171,094  
    $3.74  

    Granted